ADC Therapeutics share price logo

ADC Therapeutics

NYSE: ADCT

$1.31

-0.01

(-0.76%)

as on

ADC Therapeutics Stock Performance

as on September 4, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $1.30
    $1.37
    downward going graph

    0.76%

    Downside

    4.58%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.78
    $4.98
    downward going graph

    40.49%

    Downside

    280.15%

    Upside

    downward going graph

ADC Therapeutics share price movements today

Previous Close
$1.32
Open
$1.32
Volume
2.8M
Market Cap
$158.3M
Day's Low - High
$1.30 - $1.37
52 Week Low - High
$0.78 - $4.98

ADC Therapeutics Historical Returns

1 Month Return
+ 18.1 %
3 Month Return
-60.88 %
1 Year Return
-60 %
3 Year Return
+ 1.64 %
5 Year Return
-95.87 %

ADC Therapeutics Stock Fundamentals & Key Indicators

Check ADC Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$158.3M

EPS (TTM)

-0.76

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-93.7M

Revenue (TTM)

79.6M

Profit Margin

-121.77%

Return On Equity TTM

-705.53%

ADC Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of ADC Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
ADC Therapeutics image
ADC Therapeutics
BUY$158.3M-95.87%NA-121.77%NA
United Therapeutics image
United Therapeutics
BUY$22.0B141.49%16.5886.14%NA
Viatris image
Viatris
HOLD$19.0B9.91%-46.4434.83%2.87%
Haleon PLC Sponsored ADR image
Haleon PLC Sponsored ADR
BUY$44.4BNA20.4714.55%121.78%
Zoetis image
Zoetis
BUY$31.9B-63.08%12.4770.87%2.76%
See all

Stock Returns calculator for ADC Therapeutics Stock including INR - Dollar returns

The ADC Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

ADC Therapeutics investment value today

Current value as on today

₹45,330

Returns

-₹54,670

(-54.67%)

Returns from ADC Therapeutics Stock

-₹57,742 (-57.74%)

Dollar Impact

₹3,072 (+3.07%)

Analyst Recommendation on ADC Therapeutics Stock

Based on 4 analysts

BUY

50.00%

Buy

50.00%

Hold

0.00%

Sell

Based on 4 analysts, 50% of analysts recommend a 'BUY' rating for ADC Therapeutics. Average target price of $3.33

ADC Therapeutics Share Price Target

Get share price movements and forecasts by analysts on ADC Therapeutics.

What analysts predicted

60.66%UPSIDE

Target Price

$3.33

Current Price

$1.31

Analyzed by

4 Analysts

Target

$3.33

ADC Therapeutics target price $3.33, a slight upside of 60.66% compared to current price of $1.31. According to 4 analysts rating.

Indian Investors' Interest in ADC Therapeutics Stock

Search interest for ADC Therapeutics Stock has increased by 18% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:18% versus previous 30 day period

ADC Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
18
17
18
16
23
18
16
23
20
19
Gross Profit
15
16
17
15
20
18
15
21
16
16
Operating Income
-33
-29
-35
-32
-28
-44
-30
-18
-25
-25
EBITDA
-32
-22
-29
-18
-25
-41
-27
6
-20
-45
Interest Expense
12
12
13
11
12
12
13
13
12
13
Depreciation
0
0
0
0
0
0
0
0
0
-
Income Before Tax
-46
-36
-43
-31
-38
-55
-40
-6
-32
-16
Income Tax Expense
0
0
0
0
0
1
0
0
-
-
Net Income
-46
-36
-43
-30
-38
-56
-40
-6
-32
-16
Net Profit Margin
-258.16%
-209.90%
-238.13%
-181.71%
-167.59%
-300.68%
-249.38%
-27.80%
-164.57%
-86.06%

ADC Therapeutics Annual Profit & Loss

All numbers in Millions USD

Sep 2020
Dec 2020
Sep 2021
Dec 2021
Sep 2022
Dec 2022
Sep 2023
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
33
33
209
209
69
69
70
81
Gross Profit
-
-141
-
32
-
206
-
67
64
73
Operating Income
-
-219
-
-261
-
-123
-
-165
-130
-108
EBITDA
-
-218
-
-230
-
-107
-
-145
-102
-89
Interest Expense
-
4
-
18
-
36
-
46
50
51
Depreciation
-
2
-
2
-
2
-
2
3
1
Income Before Tax
-
-245
-
-251
-
-156
-
-200
-157
-142
Income Tax Expense
-
0
-
-21
-
0
-
39
0
0
Net Income
-246
-246
-230
-230
-155
-157
-240
-240
-157
-142
Net Profit Margin
0.00%
0.00%
-678.20%
-678.20%
-74.22%
-74.86%
-345.11%
-345.11%
-222.83%
-175.31%

ADC Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-36
-43
-30
-38
-56
-40
-6
-32
-16
Operating Cash Flow
-32
-25
-21
-56
-24
-29
-31
-29
-11
Investing Cash Flow
0
0
0
0
0
0
0
0
0
Financing Cash Flow
98
0
-1
0
93
0
58
0
0
Change in Cash
65
-25
-23
-56
69
-29
26
-30
-11

ADC Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-123
-116
-246
-230
-155
-240
-157
-142
Operating Cash Flow
-121
-121
-168
-233
-136
-118
-123
-141
Investing Cash Flow
-2
-2
-2
-6
-2
-3
0
0
Financing Cash Flow
0
100
494
267
0
73
97
150
Change in Cash
-123
-23
323
27
-139
-47
-27
10

Mutual Funds that own ADC Therapeutics Stock

Check out the Mutual Funds with significant holdings in ADC Therapeutics.

Funds
Holdings
Shares Held
MUTUAL FUND SERIES TRUST
4.466012%
5701655
Fidelity Salem Street Trust
0.847501%
1081986
VANGUARD SCOTTSDALE FUNDS
0.40079%
511680
SCHWAB CAPITAL TRUST
0.175738%
224361
TIAA-CREF Funds
0.09578%
122281
See all

Global Institutional Holdings in ADC Therapeutics

Funds
Holdings
iShares
3.89%
Vanguard
0.59%
Marcia Venegas
0.46%
SPDR
0.23%
State Street
0.06%
See all

ADC Therapeutics News & Key Events

  • img

    Today's Timeline - 04 June

    Thu, 08:13 PM

    -

    ADCT shares fell 53.4% despite positive study results due to safety concerns and adverse events in the experimental group.

Insights on ADC Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, -32.96M → -16.56M (in $), with an average increase of 99.0% per quarter

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ADCT stock has moved up by 17.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Viatris Inc. Common Stock has given 62.0% return, outperforming this stock by 121.9%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, United Therapeutics Corporation Common Stock has given 58.4% return, outperforming this stock by 50.2%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 3 quarters, 23.05M → 19.24M (in $), with an average decrease of 8.5% per quarter

About ADC Therapeutics

ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration, conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound' and ADCT-602 that is in a Phase 1/2 IIT in refractory B-cell acute lymphoblastic leukemia. Further, the company's pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, NaPi2b, and ASCT2. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
OrganisationADC Therapeutics
HeadquartersBiopOle, Epalinges, Switzerland, 1066
IndustryDrug Manufacturers - Specialty & Generic
CEODr. Ameet Mallik M.B.A., M.S.
E-voting on sharesClick here to vote

Key Management of ADC Therapeutics

Name

Title

Ms. Marcy Graham

Investor Relations Officer

Mr. Jose I. Carmona M.B.A.

Chief Financial Officer

Dr. Mohamed Zaki M.D., Ph.D.

Chief Medical Officer

Ms. Lisa Michelle Kallebo

Corporate Controller & Chief Accounting Officer

Ms. Nicole Riley

Head of Investor Relations & Corporate Communications

Ms. Kimberly Pope

Senior VP & Chief People Officer

Ms. Kristen Harrington-Smith

Chief Commercial Officer

Dr. Ameet Mallik M.B.A., M.S.

CEO & Director

Dr. David S. Ege Ph.D.

Chief Technical Officer

Mr. Peter J. Graham Esq.

Secretary and Chief Legal & Compliance Officer

FAQs

What is ADC Therapeutics share price today?

ADC Therapeutics share price today is $1.31 as on at the close of the market. ADC Therapeutics share today touched a day high of $1.37 and a low of $1.30.

What is the 52 week high and 52 week low for ADC Therapeutics share?

ADC Therapeutics share touched a 52 week high of $4.98 on and a 52 week low of $0.78 on . ADC Therapeutics stock price today i.e. is closed at $1.31,which is 73.69% down from its 52 week high and 68.03% up from its 52 week low.

What is ADC Therapeutics's market capitalisation today?

ADC Therapeutics market capitalisation is $0.00T as on .

How to invest in ADC Therapeutics Stock (ADCT) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for ADC Therapeutics on INDmoney app. Click on Buy button. You can invest as low as $1.5 in ADC Therapeutics Shares that will get you 1.1450 shares as per ADC Therapeutics share price of $1.31 per share as on September 4, 2026 at 1:29 am IST.

What is the minimum amount required to buy ADC Therapeutics Stock (ADCT) from India?

Indian investors can start investing in ADC Therapeutics (ADCT) shares with as little as ₹94.475 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹944.75 in ADC Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on ADC Therapeutics share’s latest price of $1.31 as on September 4, 2026 at 1:29 am IST, you will get 7.6336 shares of ADC Therapeutics. Learn more about fractional shares .

What are the returns that ADC Therapeutics has given to Indian investors in the last 5 years?

ADC Therapeutics stock has given -95.87% share price returns and 30.37% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?